Related Experiment Video
Updated: Aug 9, 2026

11:17
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
Published on: November 25, 2025
Repetitive Transcranial Magnetic Stimulation for Cocaine Use Disorder: An Observational Study
Laia Miquel1,2, Daniel Folch-Sanchez2,3, Pilar Lusilla-Palacios4,5,6,7
1Health and Research, Addiction Unit of Hospital Clinic of Barcelona, Spain.
Substance Use & Addiction Journal
|August 8, 2026
Summary
Repetitive transcranial magnetic stimulation (rTMS) shows promise for cocaine use disorder (CUD) treatment, reducing cravings and improving outcomes. Baseline abstinence and younger age were linked to better results and retention in this clinical study.
Area of Science:
- Neuroscience
- Psychiatry
- Addiction Medicine
Background:
- Cocaine use disorder (CUD) has high relapse rates and limited effective treatments.
- Repetitive transcranial magnetic stimulation (rTMS) is a potential therapeutic option, but clinical evidence is limited.
- This study investigates the real-world effectiveness of rTMS for CUD.
Purpose of the Study:
- To evaluate the clinical outcomes of rTMS in patients with CUD.
- To identify factors associated with treatment success and relapse.
- To assess the safety and feasibility of rTMS in a naturalistic setting.
Main Methods:
- A retrospective study of 93 CUD patients treated with rTMS between 2018-2021.
- rTMS involved 32 sessions of high-frequency (10 Hz) left dorsolateral prefrontal cortex stimulation.
- Data collected included sociodemographics, cocaine use, psychopathology, and treatment dropout.
Main Results:
- Baseline abstinence predicted lower relapse risk (OR 1.42-1.95) and higher treatment completion (70.3%).
- Abstinence probability was 58.6% for baseline abstinent patients vs. 33.6% for active users.
- Craving, anxiety, and depressive symptoms significantly decreased over time (P < .001); sleep quality also improved.
Conclusions:
- rTMS is associated with reduced craving and improved clinical outcomes in CUD patients.
- Baseline abstinence and younger age correlate with lower relapse rates and better treatment retention.
- rTMS appears to be a safe and promising adjunctive therapy for CUD.
